Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Journal for Immunotherapy of Cancer|August 11, 2019
Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1Suzanne Thomas, Linta Kuncheria, Victoria Roulstone, et al.
Journal for Immunotherapy of Cancer|July 24, 2021
Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapiesVictoria Roulstone, David Mansfield, Robert J Harris, et al.
NPJ Breast Cancer|March 6, 2021
Proteomics of REPLICANT perfusate detects changes in the metastatic lymph node microenvironmentJulia Stevenson, Rachel Barrow-McGee, Lu Yu, et al.
Molecular Therapy Oncolytics|July 11, 2018
Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 VirusNicola E Annels, Mehreen Arif, Guy R Simpson, et al.
Journal of the National Cancer Institute|April 24, 2020
Computational Image Analysis of T-Cell Infiltrates in Resectable Gastric Cancer: Association with Survival and Molecular SubtypesBenjamin R Challoner, Katharina von Loga, Andrew Woolston, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 27, 2015
BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER StressVictoria Roulstone, Malin Pedersen, Joan Kyula, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 20, 2019
PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue SarcomaHenry G Smith, David Mansfield, Victoria Roulstone, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 16, 2013
Optimising measles virus-guided radiovirotherapy with external beam radiotherapy and specific checkpoint kinase 1 inhibitionYann Touchefeu, Aadil A Khan, Gerben Borst, et al.
Expert Opinion on Biological Therapy|February 19, 2020
Combination therapy with oncolytic viruses and immune checkpoint inhibitorsMatthew Chiu, Edward John Lloyd Armstrong, Vicki Jennings, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 6, 2019
Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder CancerNicola E Annels, David Mansfield, Mehreen Arif, et al.
Pageof 3